Published on 22 Feb 2024 on GuruFocus.com via Yahoo Finance
C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates
Revenue: Reported a decrease to $20.8 million for the year ended December 31, 2023, from $31.1 million in the previous year.R&D Expenses: Remained relatively flat at $117.7 million compared to $117.8 million in the previous year.G&A Expenses: Slightly decreased to $42.1 million from $42.8 million year-over-year.Net Loss: Increased to $132.5 million, with a net loss per share of $2.67.Cash Position: Ended the year with $281.7 million in cash, cash equivalents, and marketable securities.Financial Guidance: Cash runway expected to fund operations into 2027.Business Milestones: Progress in clinical trials and strategic collaborations set to drive future growth.
Warning! GuruFocus has detected 5 Warning Signs with CCCC.
